The findings arrive at a moment when the clinical rationale for prebiopsy imaging has never been stronger. Multiple randomized trials have demonstrated that imaging the prostate before obtaining tissue, and then using those images to target suspicious lesions, detects more of the clinically significant, aggressive cancers that genuinely threaten a patient’s life, while reducing the detection of indolent tumors that might otherwise trigger unnecessary treatment. This evidence base has prompted professional guidelines to progressively strengthen their endorsement of MRI as a standard step before needles are placed. What had remained unknown until now, however, was whether that accumulating evidence had actually changed what happens in hospitals and clinics across the country.

To answer that question, the research team, including lead clinical research biostatistician Stephen Rhodes of the UH Urology Institute, turned to Epic Cosmos, a large-scale database built from electronic health records spanning many health systems nationwide. Unlike earlier studies that relied on insurance claims data, which often lag behind real-world practice and miss patients whose care crosses different payers, the electronic health record approach captures what actually happened to individual patients at the point of care. The scale of the dataset, encompassing more than half a million biopsies over nearly a decade, allowed the researchers to track utilization trends with unusual granularity, including how patterns differed by whether a man was undergoing his first biopsy or a repeat procedure after a previously negative result.

The trajectory was striking in both groups, but for slightly different reasons. Among men with a prior negative biopsy, where the evidence supporting MRI was established earliest and where the procedure has long been recommended to help explain persistent elevations in prostate-specific antigen, MRI use rose from 38 percent in 2017 to 67 percent by the first half of 2026. Among biopsy-naive men, the increase was even more dramatic in relative terms, nearly a fivefold rise over the study period. Rhodes described the pace of change as genuinely rapid, noting that the timing tracks closely with the publication of the major randomized trials and their successive adoption into clinical guidelines. In an era when many evidence-based practices take fifteen to twenty years to diffuse into routine care, a near-complete transformation of biopsy practice within less than a decade represents an unusually swift example of evidence translation.

Yet the study’s authors are careful to emphasize that the story is one of substantial progress coexisting with persistent gaps. A full third of men undergoing a first prostate biopsy are still not receiving an MRI beforehand, which means the procedure is being performed, in effect, blind. That matters because the decision to image first changes two things simultaneously: whether a biopsy is needed at all, and, if it is, exactly where the needles should go. A man whose MRI shows no suspicious lesions may be spared the procedure entirely, avoiding the discomfort, bleeding risk, infection risk, and potential overdiagnosis that accompany blind sampling. A man whose scan reveals a concerning lesion can undergo targeted biopsies that are far more likely to find an aggressive cancer if one is present. Skipping the scan forfeits both benefits at once.

The senior author of the study, Jonathan Shoag, MD, Chief of the Division of Urologic Oncology and Director of the Prostate Cancer Program at University Hospitals, framed the problem in terms of quality measurement and equity. He noted that the true scope of the shortfall had been difficult to pin down before this analysis, with the best prior data, derived from insurance claims through 2022, suggesting MRI was used in only about 30 percent of biopsies. The motivation for the new study, he explained, was to establish a current, national picture: how many men are getting an MRI before biopsy today, and whether everyone is benefiting equally. Shoag said he still regularly sees patients who were biopsied at other institutions without a preceding MRI, and he attributes part of the persistent gap to access barriers and issues with insurance coverage, a well-recognized national problem that the new data now illuminate more clearly.

The analysis also surfaced patterns that the researchers found worth examining rather than simply accepting. MRI use fell off in two specific groups: men with very high PSA levels and men over the age of 80. In some cases, the authors suggest, this may reflect reasonable clinical judgment, since a markedly elevated PSA in an older patient may prompt an urgent diagnostic pathway in which imaging is perceived as a delay, and life expectancy considerations may alter the calculus for men in their ninth decade. But the researchers caution that these patterns deserve scrutiny rather than assumption. If otherwise appropriate candidates for imaging are being sent directly to biopsy out of habit, expedience, or lack of access, a measurable quality gap exists that health systems can and should audit. The study’s practical message for institutions is direct: track your own MRI rates by patient group, compare them against the evidence, and act on what the audit reveals.

Even where MRI is used, quality is not uniform, and the authors flag this as an ongoing concern for the field. Prostate MRI is a technically demanding examination that depends on scanner capability, protocol design, radiologist expertise, and structured reporting standards. A poor-quality scan can miss a clinically significant lesion, giving false reassurance, or overcall suspicious findings, triggering unnecessary biopsies. Shoag described how University Hospitals has invested in rigorously tracking MRI quality and performance and how it relates to biopsy outcomes, establishing workflows that give patients access to the latest imaging and biopsy techniques, including the transperineal approach, which carries a lower infection risk than the traditional transrectal route. He noted that the institution participated in the clinical trials that established these techniques as standards and has built a program to offer targeted biopsy with sedation to all patients, while also being an early adopter that made MRI accessible across its patient population.

Beyond the numbers, the study highlights how the diagnostic journey itself is being restructured around advanced imaging. Shoag described a coordinated model in which patients with elevated PSA levels are navigated through evaluation and decision-making, supported by a point-of-service scheduling initiative that books imaging and follow-up appointments before patients leave the office. The goal is to compress the interval between an abnormal screening result and a definitive answer, reducing the anxiety and drop-off that can occur when patients must coordinate multiple appointments across weeks. The institution is currently involved in multiple studies testing new tools to further improve prostate cancer diagnosis, suggesting that the rapid diffusion documented in this paper may be followed by another wave of refinements in how men are evaluated for the disease.

For patients, the study’s most actionable conclusion may be the simplest: any man facing a prostate biopsy should be asking whether an MRI beforehand is appropriate for him. For clinicians and health systems, the paper provides both a benchmark and a warning, documenting extraordinary progress in translating randomized trial evidence into practice while quantifying the gap that remains. With two thirds of men now imaged before their first biopsy and more than two thirds before repeat procedures, prebiopsy MRI has decisively entered the mainstream of American prostate cancer care. The remaining task, the authors suggest, is to close the residual gaps in access, coverage, and quality so that the benefits of targeted, image-guided diagnosis extend to every patient who stands to gain from them, rather than to a fortunate majority.

Subject of Research: National trends in prebiopsy MRI utilization for prostate cancer detection in the United States

Article Title: University Hospitals researchers find major increase in the use of MRI before prostate biopsy

Article References: University Hospitals researchers find major increase in the use of MRI before prostate biopsy. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: prostate cancer, prebiopsy MRI, prostate biopsy, JAMA Oncology, University Hospitals, mpMRI imaging, targeted biopsy, transperineal biopsy, PSA screening, clinical guidelines, healthcare quality, Epic Cosmos

Traditional prostate-specific antigen (PSA) testing, the standard diagnostic tool for prostate cancer, suffers from notable drawbacks such as delayed detection and limited specificity, often leading to diagnostic uncertainty and delayed treatment interventions. The new study, recently published in BMC Cancer, proposes that molecular imaging using NRP2-targeted microbubbles (MBs_NRP2) could fill this crucial gap, enabling clinicians to visualize and quantify disease progression with unprecedented accuracy and speed.

Central to the researchers’ strategy is the identification and targeting of NRP2, a receptor prominently upregulated on endothelial cells within tumor-associated neovasculature during prostate cancer evolution. Utilizing sophisticated immunofluorescence techniques, the team confirmed a strong colocalization of NRP2 with CD31, an established endothelial marker, in prostate cancer tissue samples. This finding provided a robust biological foundation for the development of their innovative imaging agents.

Building upon this discovery, the scientists engineered microbubbles conjugated specifically to NRP2 to enhance their selective binding to tumor microvasculature. These microbubbles, when administered systemically, demonstrated remarkable precision in adhering to endothelial cells expressing NRP2, a phenomenon verified under dynamic flow conditions using parallel plate flow chamber experiments. This dynamic validation underscores the clinical relevance of MBs_NRP2 in mimicking physiological blood flow environments.

The researchers further explored the biological interplay between prostate cancer cells and endothelial cells through intricate co-culture systems replicating the tumor microenvironment. Analysis of these co-cultures revealed that as prostate cancer advances toward a castration-resistant state, endothelial cells exhibit a progressive increase in NRP2 expression. This escalation correlates with enhanced angiogenic activity, potentially driving the aggressive neovascularization characteristic of advanced prostate tumors.

To elucidate these cellular dynamics, the team employed a multi-modal analytical framework comprising immunofluorescence localization, flow cytometry, western blotting, and angiogenesis assays. This comprehensive approach offered detailed insights into how NRP2 expression varies alongside tumor progression and vascular remodeling, solidifying its role as a compelling molecular target for diagnostic imaging.

The pinnacle of this research involved applying ultrasound molecular imaging (USMI) in mouse models bearing subcutaneous prostate tumors at various stages: hormone-sensitive prostate cancer (HSPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic castration-resistant prostate cancer (mCRPC). Quantitative analysis of contrast-enhanced ultrasound signals revealed significantly heightened imaging intensities in tumor-bearing mice compared to controls, with progressive increases correlating to more advanced disease stages.

These results suggest that MBs_NRP2-based USMI may serve as a sensitive biomarker for not only detecting the presence of prostate cancer but also stratifying its severity and resistance to hormonal therapy. Such stratification is pivotal in guiding personalized therapeutic decisions and improving patient outcomes, especially considering the poor prognosis associated with CRPC.

Another remarkable aspect of this technology is its non-invasive nature and real-time imaging capability. Unlike conventional diagnostic tests prone to false positives or lengthy procedural delays, ultrasound molecular imaging offers a rapid, safe, and repeatable method to monitor molecular changes in tumor vasculature over time, potentially enabling clinicians to detect resistance emergence earlier and adjust treatment regimens proactively.

The development of MBs_NRP2 showcases the increasing convergence of molecular biology, bioengineering, and clinical imaging. By harnessing specific molecular targets like NRP2 on neovascular endothelial cells, researchers can design contrast agents that provide functional insights rather than solely anatomical information, revolutionizing cancer diagnostics.

Looking ahead, the translation of this promising preclinical work into clinical settings poses exciting opportunities and challenges. Scaling the production of NRP2-targeted microbubbles, regulatory approvals, and validation through large-scale clinical trials will be essential milestones toward establishing this technique as a routine tool in prostate cancer management.

Moreover, this research opens avenues for exploring similar molecular imaging strategies targeting other cancer types characterized by aberrant angiogenesis and receptor expression. The modular nature of microbubble design allows for adaptation to various molecular targets, positioning ultrasound molecular imaging at the forefront of precision oncology diagnostics.

The implications of early and accurate CRPC diagnosis are profound. CRPC is notoriously difficult to treat, often demonstrating resistance to conventional androgen deprivation therapies. Early detection through advanced imaging could drastically alter the clinical course by enabling timely intervention, potentially improving survival rates and quality of life for thousands of patients worldwide.

In sum, the MBs_NRP2-based ultrasound molecular imaging platform represents a significant leap forward in cancer imaging technology. It transcends current diagnostic limitations by providing a sensitive, specific, and dynamic visualization method for prostate cancer neovascularization, particularly during the critical transition to castration resistance.

As the field of molecular imaging continues to evolve, innovations like these not only enhance our diagnostic arsenal but also deepen our understanding of tumor biology and progression. They epitomize an era where interdisciplinary efforts yield transformative clinical tools, bringing hope to patients facing some of the most challenging cancers.

This pioneering research underscores the vast potential of targeted ultrasound contrast agents and sets the stage for future studies aimed at refining molecular diagnostics and ultimately improving patient care pathways within oncology.

Subject of Research:
Article Title: MBs_NRP2-based ultrasound molecular imaging for early diagnosis of castration-resistant prostate cancer
Article References:
Wang, N., Xu, X., Zhong, Y. et al. MBs_NRP2-based ultrasound molecular imaging for early diagnosis of castration-resistant prostate cancer. BMC Cancer 25, 769 (2025). https://doi.org/10.1186/s12885-025-14143-7
Image Credits: Scienmag.com
DOI: https://doi.org/10.1186/s12885-025-14143-7